SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

doi:10.1038/s41591-021-01285-x

. 2021 Apr;27(4):622-625.

doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer¹, Frances Ayres¹, Tandile Hermanus¹, Mashudu Madzivhandila¹, Prudence Kgagudi¹, Brent Oosthuysen¹, Bronwen E Lambson^{1

2}, Tulio de Oliveira³, Marion Vermeulen⁴, Karin van der Berg^{4

5}, Theresa Rossouw⁶, Michael Boswell⁷, Veronica Ueckermann⁷, Susan Meiring¹, Anne von Gottberg^{1

8}, Cheryl Cohen^{1

9}, Lynn Morris^{1

2}, Jinal N Bhiman^#^{1

10}, Penny L Moore^#^{11

12}

Affiliations

¹ National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
² Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
³ KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Department of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa, Durban, South Africa.
⁴ South African National Blood Service, Weltevreden Park, South Africa.
⁵ Division of Clinical Haematology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
⁶ Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
⁷ Division for Infectious Diseases, Department of Internal Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, South Africa.
⁸ Department of Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁹ School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹⁰ Department of Virology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹¹ National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa. pennym@nicd.ac.za.
¹² Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. pennym@nicd.ac.za.

^# Contributed equally.

PMID: 33654292
DOI: 10.1038/s41591-021-01285-x

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al. Nat Med. 2021 Apr.

. 2021 Apr;27(4):622-625.

doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.

Authors

Affiliations

¹ National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
² Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
³ KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Department of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa, Durban, South Africa.
⁴ South African National Blood Service, Weltevreden Park, South Africa.
⁵ Division of Clinical Haematology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
⁶ Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
⁷ Division for Infectious Diseases, Department of Internal Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, South Africa.
⁸ Department of Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁹ School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹⁰ Department of Virology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
¹¹ National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa. pennym@nicd.ac.za.
¹² Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. pennym@nicd.ac.za.

^# Contributed equally.

PMID: 33654292
DOI: 10.1038/s41591-021-01285-x

Abstract

SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines.

PubMed Disclaimer

Update of

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson BE, de Oliveira T, Vermeulen M, van der Berg K, Rossouw T, Boswell M, Ueckermann V, Meiring S, von Gottberg A, Cohen C, Morris L, Bhiman JN, Moore PL. Wibmer CK, et al. bioRxiv [Preprint]. 2021 Mar 1:2021.01.18.427166. doi: 10.1101/2021.01.18.427166. bioRxiv. 2021. Update in: Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x PMID: 33501446 Free PMC article. Updated. Preprint.

Cited by

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.
Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES; mRNA-1273 Study Group; Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott A, Doria-Rose NA. Pegu A, et al. bioRxiv [Preprint]. 2021 May 16:2021.05.13.444010. doi: 10.1101/2021.05.13.444010. bioRxiv. 2021. Update in: Science. 2021 Sep 17;373(6561):1372-1377. doi: 10.1126/science.abj4176 PMID: 34031659 Free PMC article. Updated. Preprint.
Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa.
Okoh OS, Nii-Trebi NI, Jakkari A, Olaniran TT, Senbadejo TY, Kafintu-Kwashie AA, Dairo EO, Ganiyu TO, Akaninyene IE, Ezediuno LO, Adeosun IJ, Ockiya MA, Jimah EM, Spiro DJ, Oladipo EK, Trovão NS. Okoh OS, et al. medRxiv [Preprint]. 2021 May 19:2021.05.17.21257341. doi: 10.1101/2021.05.17.21257341. medRxiv. 2021. Update in: iScience. 2022 Mar 18;25(3):103880. doi: 10.1016/j.isci.2022.103880 PMID: 34031660 Free PMC article. Updated. Preprint.
Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders.
Chuang ST, Buchwald P. Chuang ST, et al. Pharmaceuticals (Basel). 2022 Aug 30;15(9):1084. doi: 10.3390/ph15091084. Pharmaceuticals (Basel). 2022. PMID: 36145305 Free PMC article.
Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection.
Ko SH, Radecki P, Belinky F, Bhiman JN, Meiring S, Kleynhans J, Amoako D, Guerra Canedo V, Lucas M, Kekana D, Martinson N, Lebina L, Everatt J, Tempia S, Bylund T, Rawi R, Kwong PD, Wolter N, von Gottberg A, Cohen C, Boritz EA. Ko SH, et al. Nat Commun. 2024 Aug 22;15(1):7240. doi: 10.1038/s41467-024-51539-8. Nat Commun. 2024. PMID: 39174553 Free PMC article.
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants.
Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, Pegu A, Oloninyi OK, Ransier A, Darko S, Narpala SR, Hatcher C, Martinez DR, Tsybovsky Y, Phung E, Abiona OM, Cale EM, Chang LA, Corbett KS, DiPiazza AT, Gordon IJ, Leung K, Liu T, Mason RD, Nazzari A, Novik L, Olia AS, Doria-Rose NA, Stephens T, Stringham CD, Talana CA, Teng IT, Wagner D, Widge AT, Zhang B, Roederer M, Ledgerwood JE, Ruckwardt TJ, Gaudinski MR, Baric RS, Graham BS, McDermott AB, Douek DC, Kwong PD, Mascola JR, Sullivan NJ, Misasi J. Wang L, et al. bioRxiv [Preprint]. 2021 Mar 1:2021.02.25.432969. doi: 10.1101/2021.02.25.432969. bioRxiv. 2021. Update in: Science. 2021 Aug 13;373(6556):eabh1766. doi: 10.1126/science.abh1766 PMID: 33655252 Free PMC article. Updated. Preprint.

See all "Cited by" articles

References

1. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). - DOI
1. Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227–1230 (2020). - DOI
1. Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588 (2020). - DOI
1. Marovich, M., Mascola, J. R. & Cohen, M. S. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA 324, 131–132 (2020). - DOI
1. Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N. Engl. J. Med. 384, 238–251 (2021). - DOI

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). - DOI

[2] Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). - DOI

[3] Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227–1230 (2020). - DOI

[4] Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227–1230 (2020). - DOI

[5] Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588 (2020). - DOI

[6] Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588 (2020). - DOI

[7] Marovich, M., Mascola, J. R. & Cohen, M. S. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA 324, 131–132 (2020). - DOI

[8] Marovich, M., Mascola, J. R. & Cohen, M. S. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA 324, 131–132 (2020). - DOI

[9] Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N. Engl. J. Med. 384, 238–251 (2021). - DOI

[10] Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N. Engl. J. Med. 384, 238–251 (2021). - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Affiliations

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Authors

Affiliations

Abstract

Update of

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Abstract

Update of

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous